Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma

Pembrolizumab (Keytruda, Merck Sharp & Dohme) has a marketing authorisation as monotherapy 'for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV'.

Pembrolizumab (200 mg) is given every 3 weeks by intravenous infusion, until disease progression or unacceptable toxicity.

The list price of pembrolizumab is £2,630 per 100‑mg vial (excluding VAT; company submission).